| Today’s Big NewsDec 5, 2024 |
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now! 
|
|
| By Kevin Dunleavy Eli Lilly said it will spend $3 billion to transform a newly acquired, 84,000-square-foot plant in Kenosha, Wisconsin, into a massive complex that will produce injectables, including the company’s top-selling diabetes and obesity drugs Mounjaro and Zepbound. |
|
|
|
By Gabrielle Masson At six months, Protara Therapeutics’ investigational cell therapy elicited a complete response (CR) rate of 72% among 18 patients with bladder cancer, data that sent the biotech’s shares surging. |
By Conor Hale A federal jury has sided with Insulet over claims that the South Korea-based EOFlow had stolen trade secrets related to its wearable insulin pump, in a case that complicated Medtronic's acquisition plans late last year. |
By Nick Paul Taylor AstraZeneca has refuted allegations its staff “refuse to cooperate and respect” the U.K. marketing code. The drugmaker successfully defended itself against claims senior staff ignored requests to unlike LinkedIn posts but the U.K. marketing watchdog still found the company had brought discredit on the industry in two cases. |
|
The right funding at the right time is crucial for life sciences companies that want to fuel innovation and scale operations. Download this free whitepaper to drive innovation, expand operations and lead your organization to further success. 
|
|
By Gabrielle Masson GSK has penned another neuroscience pact, this time with Danish biotech Muna Therapeutics. The two companies will examine postmortem human brains in efforts to identify several new drug targets for Alzheimer’s disease. |
By Zoey Becker The FDA had originally pushed its decision back by three months after a November manufacturing-related delay. |
By Angus Liu As the Chinese vaccines market undergoes a seismic shift marked by disappointing sales, GSK has extended—but with reduced volumes—an ongoing shingles vaccine partnership with local powerhouse Chongqing Zhifei Biological Products. |
By Conor Hale Led by Insight Partners and joined by Battery Ventures, the nine-figure total is an extension to its prior series C round. Cleerly previously secured $223 million in mid-2022. |
By James Waldron Massachusetts-based VC shop Atlas Venture has drawn together another $450 million fund to be channeled toward innovative biotechs. |
By Fraiser Kansteiner Amgen is laying out $1 billion to build a second drug substance facility in Holly Springs, North Carolina. Together with Amgen’s existing facility in the town, the company’s investments in Holly Springs are slated to create a total of 370 new jobs. |
By Zoey Becker The U.S. Court of Appeals for the Federal Circuit sided with a prior ruling that denied Novartis' motion seeking an injunction to prevent MSN's generic rival from launching. |
By Darren Incorvaia French researchers have used a protein called receptor activator of NF-κB ligand (RANKL) to revive the structure and function of the thymus in old mice. The thymus sits in front of the heart and is where T cells mature; its age-related decline is associated with cancer, infections and autoimmune conditions, according to a Dec. 4 release about the results. |
By Kevin Dunleavy AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has blessed the PD-L1 inhibitor for limited-stage small cell lung cancer (LS-SCLC) patients who have not had disease progression after concurrent chemotherapy and radiation treatments. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
|
The European orphan drug market presents a significant opportunity, with forecasts predicting substantial growth in the coming years. Early access programs (EAPs) have emerged as a critical strategy for successfully launching rare disease therapies in this complex and diverse market. Access this whitepaper to learn more. 
|
|
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
